Dry Eye Syndrome: A Growing Multifactorial Disease

Dry eye disease (DED) is a chronic, multifactorial disease that compromises the integrity of the tear film and the ocular surface, causing dehydration, inflammation, and epithelial damage. It manifests itself with symptoms such as burning, itching, photophobia, foreign body sensation, visual fatigue, and blurred vision, which worsen in the evening or after prolonged visual exposure.

It is estimated that the syndrome affects at least 10% of the world population, with prevalences of up to 30% in the elderly and over 50% in contact lens wearers. Women are more affected than men (60% vs 40%), with a peak incidence in perimenopausal age, due to hormonal factors that alter the stability of the tear film.
The incidence is rapidly increasing in urban and industrialized contexts, due to the intensive use of digital devices and environmental exposure to irritants, such as air conditioning, pollution and low relative humidity.

The causes of dry eye syndrome are various and often coexisting:

• Tear gland dysfunction: reduced water secretion.
• Tear film instability: increased evaporation due to reduced blink frequency (VDT syndrome).
• Chronic inflammation: involvement of pro-inflammatory cytokines and free radicals.
• Systemic pathologies: systemic lupus erythematosus, rheumatoid arthritis, diabetes.
• Latrogenesi: refractive surgery (e.g. LASIK), prolonged use of topical medications.

The disorder is not only ocular, but systemic: it affects the quality of life, limiting daily activities such as reading, driving at night or using the computer. In severe cases, it can compromise visual function, expose to infections and generate structural alterations of the cornea. Given its inflammatory and degenerative nature, dry eye syndrome requires a therapeutic approach aimed not only at re-establishing ocular hydration, but also at modulating inflammation and protecting the epithelial surface from oxidative stress.

CurIAL βeta^TM: Complete support for eye health from within

CurIAL βeta ^™ is a dietary supplement in capsule form formulated to support visual health and combat the symptoms of dryness and ocular inflammation. Its synergistic and exclusive formulation includes ExceptionHYAL® Wink sodium hyaluronate, CurCura® (highly bioavailable curcumin), and astaxanthin. Thanks to its combined action, CurIAL βeta ^™ deeply hydrates the ocular surface, reduces oxidative stress, and attenuates inflammatory processes, offering long-lasting relief compared to traditional eye drops. It is indicated for those suffering from dry eyes, visual fatigue, or inflammation induced by intensive screen use. Gluten- and lactose-free, it is also suitable for vegans and those with food intolerances.

ExceptionHYAL® Wink is a biotechnological ingredient obtained through the exclusive HATech 2.0® technology, based on second-generation hyaluronans, characterized by a broad and specific spectrum of molecular weights (from 50 to 3000 kDa), clinically tested to promote rehydration and regeneration of ocular tissues by acting from within. It allows for a progressive and synergistic release in the gastrointestinal tract and stimulates the neosynthesis of endogenous hyaluronic acid in ocular tissues. Its main documented actions are:

• Deep and long-lasting hydration of the ocular surface: stimulates the production of GAGs and Aquaporin-3, facilitating the transport of water into dehydrated tissues.
• Immediate relief from symptoms: gives relief from dryness, irritation o discomfort both at the ocular and mucous membrane level, significantly improving well-being and the sensation of visual comfort.
• Protective film-forming effect: helps to rebuild the altered mucosal barrier, limiting the evaporation of the tear film.
• Improved tolerance to blue light: documented reduction of photophobia and visual discomfort.
• Stimulation of tissue regeneration: 20% increase in protein synthesis in keratinocytes, essential for epithelial integrity.

In a controlled clinical study, taking 200 mg/day of ExceptionHYAL® Wink resulted in:

• To a OSDI score reduction from 25,1 to 11,9 in 60 days, going from a severe dry eye condition to a normal state.
• A decrease in associated symptoms: -36% sensitivity to light, -44% difficulty reading, -32% discomfort when watching TV.
• To a improvement in perceived quality of life in 76% of participants.

CurCura® is a full spectrum extract with high bioavailability that contains curcumin I, II and III in natural proportions, integrated with sesquiterpenes that increase its absorption. Its main actions include:

• Deep anti-inflammatory activity: inhibition of pro-inflammatory cytokines (IL-6, IL-8, IL-1β), which are fundamental in the pathogenesis of ocular inflammation
• Powerful antioxidant activity, validated with DPPH tests comparable to Trolox
• Cellular protection and tissue regeneration at the level of the corneal surface

Unlike other isolated forms, the CurCura® phytocomplex preserves the integrity and synergy of the natural components, ensuring an effective and well-tolerated systemic action.

Derived from the microalgae Haematococcus pluvialis, this form of astaxanthin is highly concentrated and purified, with a molecular structure that ensures superior stability and bioavailability. Its main functions are:

• Neutralization of free radicals and reduction of retinal oxidative stress
• Improved ocular microcirculation, with increased capillary flow near the optic nerve
• Increased resistance to visual fatigue, useful in case of prolonged exposure to screens

Why choose CurIAL βeta^TM?

• Deep and long-lasting eye hydration: Thanks to sodium hyaluronate ExceptionHYAL® Wink, CurIAL βeta^TM promotes the formation of a stable protective film on the ocular surface, improving lubrication and reducing tear evaporation. Unlike eye drops, the hydrating effect lasts over time thanks to the systemic action of the active ingredient.
• Integrated and natural anti-inflammatory action: The CurCura® phytocomplex, with curcumin I, II and III, counteracts the inflammatory processes underlying dry eye syndrome. The selective inhibition of pro-inflammatory cytokines helps reduce redness, burning and ocular pain, improving overall visual well-being.
• Advanced antioxidant protection: Astaxanthin AstaZine®, one of the most powerful natural antioxidants, protects the retina and eye cells from oxidative stress induced by blue light and free radicals. This translates into greater resistance to visual fatigue and improved clarity and quality of vision.
• Full visual support even in digital environments: The synergy between the ingredients of CurIAL βeta^TM protects the macula from prolonged exposure to blue light emitted by electronic device screens. It is ideal for those who work long hours at the computer or frequently use smartphones and tablets.
• Tangible clinical evidence: Clinical studies demonstrate a significant reduction in OSDI (Dry Eye Test) scores in just 30 days, with continued improvement for up to 60 days. Data confirms a 45% reduction in reading difficulties and a 35% reduction in redness symptoms.
• Safe, well tolerated and easy to integrate formula: CurIAL βeta^TM It is gluten and lactose free, also suitable for vegans or those with food intolerances. Its daily intake (1 capsule per day) makes it easy to integrate into the daily routine, without gastrointestinal side effects.
  

MEDIA ANALYSIS AND INGREDIENTS CurIAL βeta^tm

AVERAGE ANALYSIS FOR 1 CAPSULE:

INGREDIENTS
ExceptionHYAL® Wink (Sodium hyaluronate); capsule shell: vegetable gelatin, CurCura® full Spectrum Curcumin (standardized extract of Curcuma Longa L. rhizome) Curcumin I, II, III, thickener: beta cyclodextrin; anti-caking agents: corn starch, magnesium stearate, Astaxanthin.

ExceptionHYAL® is a registered trademark of ROELMI HPC SR